精准医学:万古霉素与β-内酰胺类抗菌药物TDM指导给药以最大化疗效并最小化毒性
本综述探讨抗菌药物TDM在危重症、肥胖及老年人群中的作用,重点聚焦β-内酰胺类与万古霉素。TDM旨在个体化给药以达到与改善患者结局相关的抗生素暴露。近十年β-内酰胺类TDM文献增多,万古霉素监测从谷浓度转向AUC/MIC比值。结论认为TDM在PK/PD变异大的人群中至关重要,但仍需TDM与患者结局关联的研究。
要点
- 危重症、肥胖及老年患者PK/PD变异大,TDM有助于实现治疗目标。
- 万古霉素监测正从谷浓度转向AUC/MIC比值。
- β-内酰胺类TDM证据增多,但TDM与患者结局关联仍需研究。
核心结论
- 通过TDM实施精准给药正在扩展,在PK/PD改变的人群(包括危重症、肥胖及老年患者)中尤为重要。
- 由于这些人群PK/PD变异大,TDM对最大化抗菌疗效和降低不良事件率至关重要。
- 仍需要将TDM与患者结局联系起来的研究。
- 通过β-内酰胺类TDM提供患者特异性治疗并转向万古霉素AUC/MIC监测可能具有挑战性,但由专家引领可实现基于PK的抗菌治疗优化。
研究设计与样本
- 本文为综述,探讨抗菌药物TDM的作用,重点聚焦β-内酰胺类与万古霉素,并特别关注危重症、肥胖及老年人群。
主要发现
- 抗菌药物耐药持续上升促使需要优化抗菌药物给药。
- TDM最初为减少窄治疗指数药物的不良反应而发展,如今患者与病原体复杂性扩大了对精准给药的需求。
- 危重症、肥胖及老年人群PK/PD改变,加上病原体敏感性下降,使达到治疗目标复杂化。
- 近十年抗菌药物TDM扩展,出现了支持β-内酰胺类TDM的文献,以及万古霉素监测从谷浓度转向AUC/MIC比值。
临床怎么用
- PK/PD专家应走在实施精准给药实践的前沿。
- 在危重症、肥胖及老年患者中应通过TDM实施精准给药以最大化疗效并减少不良事件。
- 可提供β-内酰胺类TDM的患者特异性治疗,并转向万古霉素AUC/MIC监测。
局限性
- 仍需要将TDM与患者结局联系起来的研究。
- 提供患者特异性β-内酰胺类TDM并转向万古霉素AUC/MIC监测可能具有挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The goal of this review is to explore the role of antimicrobial therapeutic drug monitoring (TDM), especially in critically ill, obese, and older adults, with a specific focus on β-lactams and vancomycin. SUMMARY: The continued rise of antimicrobial resistance prompts the need to optimize antimicrobial dosing. The aim of TDM is to individualize antimicrobial dosing to achieve antibiotic exposures associated with improved patient outcomes. Initially, TDM was developed to minimize adverse effects during use of narrow therapeutic index agents. Today, patient and organism complexity are expanding the need for precision dosing through TDM services. Alterations of pharmacokinetics and pharmacodynamics (PK/PD) in the critically ill, obese, and older adult populations, in conjunction with declining organism susceptibility, complicate attainment of therapeutic targets. Over the last decade, antimicrobial TDM has expanded with the emergence of literature supporting β-lactam TDM and a shift from monitoring vancomycin trough concentrations to monitoring of the ratio of area under the concentration (AUC) curve to minimum inhibitory concentration (MIC). PK/PD experts should be at the forefront of implementing precision dosing practices. CONCLUSION: Precision dosing through TDM is expanding and is especially important in populations with altered PK/PD, including critically ill, obese, and older adults. Due to wide PK/PD variability in these populations, TDM is vital to maximize antimicrobial effectiveness and decrease adverse event rates. However, there is still a need for studies connecting TDM to patient outcomes. Providing patient-specific care through β-lactam TDM and transitioning to vancomycin AUC/MIC monitoring may be challenging, but with experts at the forefront of this initiative, PK-based optimization of antimicrobial therapy can be achieved.
引用
- Cusumano JA, Klinker KP, Huttner A, et al. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity. Am J Health Syst Pharm. 2020. PMID: 32537644. doi:10.1093/ajhp/zxaa128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。